Table 1.
Characteristics among all participants enrolled in ATAHC (n= 163)
| Total study population (n=163) |
Treated (n=111) |
Untreated HCV RNA positive at enrolment (n=34) |
Untreated HCV RNA negative at enrolment (n=18) |
|
|---|---|---|---|---|
| Male, n (%) | 116 (71%) | 83 (75%) | 22 (65%) | 11 (61%) |
| Age (yrs), mean ±SD | 34.3 ± 9.9 | 34.5 ± 10.4 | 34.7 ± 9.0 | 32.2 ± 8.4 |
| Tertiary education or greater, n (%) | 66 (40%) | 51 (46%) | 9 (26%) | 6 (33%) |
| Full-time or part-time employment, n (%) | 63 (39%) | 52 (47%) | 9 (26%) | 2 (11%) |
| Methadone or buprenorphine treatment | ||||
| Ever (not current) | 17 (10%) | 12 (11%) | 4 (12%) | 1 (6%) |
| Current | 22 (14%) | 12 (11%) | 6 (18%) | 4 (22%) |
| Social functioning score, median (IQR)* | 13 (8–18) | 11 (6–17) | 15 (9–19) | 18 (13–20) |
| Injecting drug use ever, n (%) | 124 (76%) | 84 (76%) | 28 (82%) | 12 (67%) |
| Injected over the past month, n (%)† | 53 (43%) | 31 (37%) | 15 (54%) | 7 (58%) |
| HIV infection, n (%) | 50 (31%) | 37 (33%) | 11 (32%) | 2 (11%) |
| Hepatitis B virus (HBV) surface antigen, n (%) | 2 (1%) | 1 (1%) | 0 (0%) | 1 (6%) |
| Log10 HCV RNA - screening, median (log IU/L) | 5.6 | 5.8 | 4.0 | 0 |
| HCV genotype | ||||
| Genotype 1 | 75 (46%) | 62 (56%) | 13 (38%) | 0 |
| Genotype 2 | 6 (4%) | 4 (4%) | 2 (6%) | 0 |
| Genotype 3 | 56 (34%) | 40 (36%) | 16 (47%) | 0 |
| Genotype 4 | 1 (1%) | 0 (0%) | 1 (3%) | 0 |
| Missing genotype | 25 (15%) | 5 (4%) | 2 (6%) | 18 (100%) |
*
IQR (interquartile range),
†
among participants who reported injecting